Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

ZNTL has been the topic of a number of other research reports. Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Finally, Wedbush reiterated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL traded down $0.21 during mid-day trading on Thursday, reaching $1.61. 229,060 shares of the company's stock were exchanged, compared to its average volume of 1,529,924. The business's fifty day simple moving average is $2.04 and its 200-day simple moving average is $2.85. The stock has a market capitalization of $115.26 million, a PE ratio of -0.64 and a beta of 1.75. Zentalis Pharmaceuticals has a 52-week low of $1.60 and a 52-week high of $16.27.

Remove Ads

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. Equities research analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares of the company's stock, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the company's stock in a transaction on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares of the company's stock, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Integral Health Asset Management LLC acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $3,182,000. Verition Fund Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock valued at $5,536,000 after acquiring an additional 951,500 shares during the period. Almitas Capital LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 69.3% during the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock valued at $4,929,000 after acquiring an additional 665,968 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at about $1,364,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Zentalis Pharmaceuticals by 75.7% during the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after purchasing an additional 370,511 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.